SCHEMBL3451827

SCHEMBL3451827

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2NCCOC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.49
STK17A Q9UEE5 4/20 0.48
STK17B O94768 3/20 0.46
PIK3CA P42336 1/20 0.42
BRAF P15056 2/20 0.41
JAK2 O60674 1/20 0.41
FLT1 P17948 1/20 0.41
JAK1 P23458 1/20 0.41
FLT4 P35916 1/20 0.41
BLK P51451 1/20 0.41
JAK3 P52333 1/20 0.41
TBK1 Q9UHD2 1/20 0.41
EGFR P00533 3/20 0.41
ERBB2 P04626 1/20 0.41
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
SIRT5 Q9NXA8 2/20 0.40
ITK Q08881 2/20 0.40
AXL P30530 1/20 0.40
PAK1 Q13153 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447211 0.95 STK17A (0.51) CSNK2A1STK17ASTK17BJAK2FLT1
SCHEMBL3448587 0.93 STK17A (0.50) CSNK2A1STK17ASTK17BEGFRERBB2
SCHEMBL3451090 0.92 STK17A (0.47) CSNK2A1STK17ASTK17BEGFRERBB2
SCHEMBL13310882 0.91 STK17A (0.46) CSNK2A1STK17ASTK17BEGFRERBB2
SCHEMBL3448505 0.90 CSNK2A1 (0.57) CSNK2A1STK17ASTK17BPIK3CABRAF
SCHEMBL3452481 0.90 STK17A (0.49) CSNK2A1STK17ASTK17BEGFRERBB2
SCHEMBL3450274 0.90 STK17A (0.49) CSNK2A1STK17ASTK17BJAK2FLT1
SCHEMBL3449601 0.90 CSNK2A1 (0.48) CSNK2A1STK17ASTK17BJAK2FLT1
SCHEMBL3448259 0.89 STK17A (0.42) CSNK2A1STK17ASTK17BEGFRERBB2
SCHEMBL3448849 0.89 SYK (0.49) CSNK2A1STK17ASTK17BEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CSNK2A1 1858/4885STK17A 1984/4885STK17B 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.